Sanofi Sees Strength In Regional Volatility, GSK Lowers Revenue Target After Price Cuts – Emerging Market Earnings Roundup (Part 4)
This article was originally published in PharmAsia News
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.
You may also be interested in...
Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.
In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 1 of 2)
Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.
Eli Lilly & Co. Inc. has been rumored to be in partnership talks with Turkish Mustafa Nevzat Pharmaceuticals. The U.S. drug maker is reportedly looking for a minority stake in the Turkish generics maker